Germline <i>BRCA</i> pathogenic variants and hematologic adverse events in patients with ovarian carcinoma receiving PARP inhibitors: a retrospective cohort study
Patients with aHGOC and a gBRCA-PV do not experience higher PARPi-related HAEs compared to non-gBRCA-PV carriers, unlike platinum salt-related HAEs.
Authors
- Enrico Derenzini (ORCID: https://orcid.org/0000-0002-7154-8140)
- Giuseppe Curigliano (ORCID: https://orcid.org/0000-0003-1781-2518)
- Silvia Derio
- Mariateresa Lapresa
- Eleonora Nicolò (ORCID: https://orcid.org/0000-0001-5042-6550)
- Dario Trapani (ORCID: https://orcid.org/0000-0003-1672-9560)
- Laura Boldrini (ORCID: https://orcid.org/0000-0001-5904-3708)
- Luca Boscolo Bielo (ORCID: https://orcid.org/0000-0003-1026-3923)
- Gloria Pellizzari (ORCID: https://orcid.org/0009-0002-5733-2316)
- Jacopo Villa (ORCID: https://orcid.org/0009-0009-9491-8317)
- Marta Mongillo (ORCID: https://orcid.org/0009-0004-4960-7759)
- Carmine Valenza (ORCID: https://orcid.org/0000-0003-1150-0345)
- Emanuela Omodeo Salè (ORCID: https://orcid.org/0000-0002-7641-8708)
- Federica Gigli (ORCID: https://orcid.org/0000-0001-5786-8183)
- Jalissa Katrini (ORCID: https://orcid.org/0009-0003-1405-0586)
- Grazia Castellano (ORCID: https://orcid.org/0000-0003-2147-1672)
- Lorenzo Guidi (ORCID: https://orcid.org/0009-0002-6618-8598)
- Nicoletta Colombo (ORCID: https://orcid.org/0000-0003-2225-715X)
- Gabriella Parma (ORCID: https://orcid.org/0000-0002-2150-0448)
Institutions
- University of Milan (IT)
- European Institute of Oncology (IT)
- University of Milano-Bicocca (IT)
Publication Details
- Journal
- The Oncologist
- Published
- 2024-11-28
- DOI
- https://doi.org/10.1093/oncolo/oyae330
- Citations
- 1
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 0.28